The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

Respect the role (and confidentiality) of the EAB at UCSD—and at all NCI-designated cancer centers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Over the years, I have gained extensive experience with academic cancer center External Advisory Boards, including hosting multiple EAB meetings at my own cancer center, chairing the EABs of nine other NCI designated cancer centers, and serving on many others. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
George J. Weiner, MD
Professor of internal medicine-hematology, oncology, and blood & marrow transplantation, Professor of pharmaceutical sciences and experimental therapeutics, CE Block Chair of Cancer Research, Director emeritus, University of Iowa Holden Comprehensive Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

Sponsored

The long life of a clinical trial
How JCO sustains landmark oncology research

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
By Journal of Clinical Oncology
Clinical Roundup

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study. 
Byline
George J. Weiner, MD
Professor of internal medicine-hematology, oncology, and blood & marrow transplantation, Professor of pharmaceutical sciences and experimental therapeutics, CE Block Chair of Cancer Research, Director emeritus, University of Iowa Holden Comprehensive Cancer Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account